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ABSTRACT
Neuroblastoma (NB) is an extracranial tumor that affects the nervous
system and accounts for approximately 650 – 800 cases diagnosed per year in
children under the age of 5 (www.cancer.org/cancer/neuroblastoma/about/keystatistics.html). NB occurs at a relatively rare rate of 10.2 per million children
under 15 years old but accounts for 12-15% of pediatric cancer death because
patients with high-risk NB (HRNB) have 5-year survival rates between 4050%(Brodeur, 2003; Park et al. 2010). Developmental biology research has
recognized neural crest cells (NCC) as the progenitor cells of NB, as tumors form
in the trunk NC derived sympathetic nervous system (Dupin, 2013; Simões-Costa
et al., 2015). Genome-wide association studies (GWAS) of these tumors reveal
several chromosomal aberrations and genes related to the development of NB
(Pugh et al., 2013; Seeger et al., 1985). Unfortunately, the heterogeneity of the
disease has revealed a low mutation frequency in suspected oncogenes, along
with an assortment of chromosomal gains and losses, resulting in a variety of
mechanisms of NB formation. These structural features demonstrate the
complexity of NB tumorigenesis and the unlikeliness of developing a single target
treatment (Matthay, K et al., 2012). Amongst all the predictors recognized in NB
formation, amplification of the MYCN gene occurs in 20% of tumors and serves
as the most significant prognosticator of poor outcomes in HRNB patients
(Brodeur, 1984). These insights have resulted in NCC experiments in mice,
zebrafish, and primary cell models to study NB development under the
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overexpression of MYCN and other oncogenes such as ALK and LMO1(Weiss et
al.,1997; Zhu et al., 2012; Olsen et al., 2017). While these models have
elucidated the association of MYCN and LMO1 overexpression in NCC to NB
formation, they lack a direct descriptive model of NB formation in human NCC.
Building off the current understanding of genes synergistically driving
neuroblastoma, I utilized H1 human embryonic stem cells (hESC) to create a cell
line inducible for LMO1 and MYCN. Through genetic engineering, and
subcloning, I created two constructs: a plasmid containing the MYCN gene under
the regulation of the Tetracycline On (TET-ON) system and the LMO1 construct
under the regulation of TET-ON. I sequenced the constructs, analyzed their
genetic composition, and found the TET-ON LMO1 suitable for integration into
the H1 hESC. After nucleofection and genetic screening, the data suggest the
production of a mixed population of H1 hESC containing a subset of cells that
appear to have integrated the TET-ON LMO1 into the AAVS1 locus at
chromosome 19. Further attempts are required for the complete development of
the H1 hESC TET- 3G LMO1 plus MYCN inducible cell line.
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CHAPTER ONE
NEURAL CREST CELL DEVELOPMENT AND ROLE IN
NEUROBLASTOMA

Overview of Neural Crest Cells
Neural crest cells (NCC) are a population of multipotent progenitor cells
that are unique to vertebrates that emerge early in development and migrate
extensively to form a multitude of derivatives (Prasad et al., 2019). NCC
differentiates into a variety of cell lineages, such as the sensory neurons and glia
of the sympathetic and parasympathetic nervous system, hormone-producing
cells of the adrenal gland, pigment-producing cells, and the connective and
structural components of the craniofacial region (Simões-Costa, M., & Bronner,
M. E. 2015). The migratory nature of NCC and their differentiation to a wide
variety of cell types is accomplished through complex spatial-temporal
intracellular and intercellular singling. Defects in NCC that produce birth defects
are classified as neurocristopathies and are responsible for various diseases,
including cleft lip/palate, Hirschsprung, Waardenburg syndromes, and cancers
such as melanoma and neuroblastoma (Guillermo et al., 2018). Therefore, to
understand the progression of neurocristopathy, researchers investigate the early
development, genetic aberrations, signaling pathways, and cellular environment
that influences improper NCC differentiation.
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Neural Crest Development
Neural crest cells are a derivate of the ectoderm and develop during
neurulation when the neural plate invaginates to form the neural tube. Research
conducted in chicken and amphibian embryos has demonstrated that neural
crest induction occurs in a two-step process. The first step involves WNT and
FGF signaling, which promotes the formation of the neural plate border tissue,
which flanks the neural plate and separates the neural and nonneural ectoderm.
The second step of the induction process involves Wnt, BMP, and Notch
pathways that are responsible for activating and maintaining neural crest cell
specificity. While the signals responsible for the formation of neural crest cells
are well characterized. There is much debate on how and what tissues interact in
neural crest cell formation.
Neural crest cells develop along most of the dorsal axis of the neural tube
and exhibit different migration patterns according to the signals received by the
neural crest cells (Prasad et al., 2019). The NC has four distinct anatomical
regions on the neural tube characterized by the derivatives they produce: cranial
NC, cardiac NC, trunk NC, vagal/sacral NC. The cranial NC migrates to the
pharyngeal arches and forms the craniofacial skeleton, parasympathetic and
sensory ganglia, and endocrine and pigment cells (Gilbert, 2000). The cardiac
NC is a subregion of the cranial NC, which develops into the neurons, cartilage,
and connective tissues of the pharyngeal arches and the muscular-connective
tissue of arteries (Gilbert, 2000; Huber. 2015). The trunk NC which forms the
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dorsal root ganglia, the sympathetic ganglia, and melanocytes. The vagal/sacral
NC form the parasympathetic ganglia of the gut, and these cell types are
dispersed along the neural tube.

Trunk Neural Crest Derivatives and Neuroblastoma Formation
NB tumors are localized to the sympathetic nervous system, particularly
the adrenal medulla has isolated the trunk NC as the population of cells involved
in tumor formation. The trunk NC has two avenues of migration: the dorsolateral
and the ventrolateral pathway. The dorsolateral pathway produces skin
melanocytes, while the ventrolateral pathway produces the dorsal root ganglia,
sympathetic ganglia, adrenal medulla, and aortic nerve clusters (Gilbert, 2000). It
is the sympathetic ganglia and specifically the adrenal medulla, that is associated
with the NB tumor formation. NB tumors are generally localized to one of the
adrenal glands, but there is a small subset of NB patients that present bilateral
tumors in both adrenal glands, suggesting NB tumorigenesis before the migration
of the NC (Pagès et al., 2009). The migratory pattern of NCC, the location of
tumors in the sympathetic chain, along with single and bilateral adrenal glands,
provides evidence that NB is a derivative of the trunk NC.
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Figure 1. Neural Tube Formation.
Representation of the Ectoderm, Neural plate borders, and the Neural plate
before the formation of the neural tube. The bottom portion of the diagram
depicts the neural tube, neural crest, and ectoderm, which developed after the
invagination of the neural plate and neural plate borders.
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CHAPTER TWO
THE GENETICS AND MODELS OF NEUROBLASTOMA

Neuroblastoma Overview
The development of a cell line project that can model NB involves
understanding the molecular and genetic features of the disease. This task
required investigation into the clinical data of high-risk neuroblastoma patients
and the emerging genome-wide association studies exploring the genomic and
genetic structures involved in cancer. Genomic analysis of HRNB tumors has
revealed the chromosomal aberrations and the genetic interactions that
correspond to clinically favorable or unfavorable outcomes in patients (Cheung,
N. K., & Dyer, M. A. 2013). There are two basic patterns of genomic
modifications that impact NB prognosis. The first being whole chromosomal gain,
which can produce a positive outcome in NB patients. The second involves
segmental chromosomal losses, gains, or a combination of both, which results in
MYCN amplification, loss of tumor suppressor function, or increased expression
of other oncogenes. The genomic survey of tumors has revealed there is no
single genetic mutation that corresponds with HRNB and reduced survival rates
(Pugh TJ). This reality required the Garcia-Castro laboratory to develop a model
that could generate neuroblastoma from the neural crest model.

5

Clinically Observed Chromosomal Aberrations in Neuroblastoma
Deletions in chromosome 1p36 occur in approximately 70% of tumors
associated with an elevated risk of recurrence in patients (Kim, S. et al., 2006).
The suspected cause of tumor formation is the loss of CHD5, a tumor suppressor
gene that regulates the proliferation of cells in the nervous system (Colon, N. C.,
& Chung, D. H., 2011). The whole chromosomal gain of chromosome 17 tends to
lead to a favorable outcome, but the somatic gain of chromosome 17q manifests
in over 50% of Neuroblastomas cases correlated with poor survival outcomes
(Van Roy et al., 2009). Chromosome 17q contains survivin/BIRC5 (an antiapoptotic protein) and nm23/NME1 (nucleoside diphosphate kinases), which
paired with MYCN overexpression lead to tumor growth and proliferation.
Another recurrent chromosomal aberration that presents a different mechanism
of NB formation is the somatic loss of chromosome 3q and 11q, which produces
NB without MYCN overexpression (Van Roy et al., 2009). Chromosomal
aberrations are indicative of failures of regulatory factors that result from a
multifaceted loss of apoptotic genes and the gain of proto-oncogenes (Cheung,
N. K., & Dyer, M. A., 2013. These aberrations have become clinically recognized
as a predictor of risk in patients with NB.
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Genes and Modes of Neuroblastoma Inheritance
MYCN belongs to the MYC family of oncogenes, whose deregulation
appears in a variety of cancers and perhaps are involved in all human tumor
formation (Dang, 2012). MYCN is located on chromosome 2p24.3 and produces
the protein N-MYC which is necessary for the proliferation of progenitor cells
during the development of the central nervous system (Knoepfler et al., 2002).
MYCN expression is observable in the early neural crest cells, and in typical
development, expression decreases as neuroblasts differentiate into their
terminal cell type (Huang, M., & Weiss, W. A., 2013). Overexpression of MYCN
appears in many cancers of the nervous system as well as nonneuronal tumors
such as prostate cancers, but MYCN is most notably associated with high-risk
neuroblastoma and poor prognosis in patients (Beltran et al., 2011; Seeger et al.,
1985). In approximately 20% of NB tumors, the MYCN gene is amplified,
presenting between 4 to 10 chromosomal copies (Modak, S., & Cheung, N. K.,
2010). Despite the known oncogenic nature of MYCN in NB, its role as a critical
transcription factor for development makes it an undesirable target for
suppression (Kushner B. H. 2004). This reality has motivated researchers to
identify the down streams pathway of N-MYC or synergistic genes that promote
NB as possible therapeutic targets.
Familial NB is inherited in an autosomal dominant manner with incomplete
penetrance that accounts for approximately 1-2% of all cases of NB (Colon, N.
C., & Chung, D. H., 2011). Familial NB patients are generally diagnosed earlier
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than sporadic cases and present many primary tumors and other clinical
hallmarks associated with NB (Smith, V., & Foster, J. 2018). The inheritance
pattern is described in the late 1960s due to cases where several siblings in a
family would develop NB tumors in the sympathetic nervous system (Knudson, A.
G., Jr, & Strong, L. C., 1972). In the mid to late 2000s, the genes PHOX2B and
ALK were identified for the role they played in the familial inheritance pattern
(Trochet et al., 2004; Janoueix-Lerosey et al., 2008). PHOX2B is a gene that
encodes for a paired homeodomain transcription factor that regulates cell cycle,
neuronal differentiation, and account for approximately 6-10% of familial cases
(Mossé et al., 2004). ALK (anaplastic lymphoma kinase) is a gene that encodes a
tyrosine kinase receptor that plays a role in neuronal differentiation, proliferation,
survival (Mossé et al., 2008). Genome sequencing has identified several
mutations in the ALK gene, which are the most aggressive type of familial NB,
causing mutation resulting in the majority of primary neuroblastoma (Schulte et
al., 2013). Familial NB, while well-characterized, remains the rarest form of NB,
and much attention has is focused on the Sporadic formation of NB.
Sporadic NB is the most typical manner that tumors develop in the
sympathetic chain, which results from somatic mutations that are not inherited.
The most common mutation observed in sporadic NB is the gain of the MYCN
gene copies, which express a high level of N-MYC protein. Genome-wide
association studies (GWAS) have identified nine other genes involved in the
pathogenesis of sporadic NB with BARD1, CASC15/14, LMO1, LIN28B, and
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HACE1 observed in high-risk tumors (Bosse, K. R., & Maris, J. M., 2016). The
LIM-domain-only (LMO1) gene, located at 11p15 is implicated across several
epidemiological studies as an NB oncogene in human tumors (Matthews, J. M.,
Lester, K., Joseph, S., & Curtis, D. J., 2013). The somatic gain of 11p results in
elevated levels of LMO1 expression, which is detected in tumors that have
metastasized (Bach, 2000). Experiments demonstrate reducing LMO1
expression with short hairpin RNA lowered the growth of NB tumors while
increasing LMO1 promotes tumor formation (Wang K, Diskin SJ, Zhang H, et al.
2011). The implications of LMO1 expression in HRNB has persuaded
researchers to develop a model to study its role in NB formation.

Current Models of Neuroblastoma Research
Clinically the overexpression of MYCN has shown an association with
neuroblastoma in several retroactive studies. However, the demonstration of
MYCN expression initiating NB formation was absent in the literature (Olsen et
al., 2017). Researchers established transgenic mice, zebrafish, and primary cell
models to observe if MYCN overexpression was sufficient to drive NB. The goal
of MYCN overexpression in a model organism is to promote tumor growth in the
sympathetic nervous system, particularly the adrenal medulla, to resemble
human neuroblastoma and identify a possible mechanism of tumorigenesis.
One of the first models that demonstrated MYCN's role in NB formation
was a transgenic mouse model that overexpressed human MYCN in migrating
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NCC. (Weiss et al. 1997). This novel murine model utilized a rat tyrosine
hydroxylase promoter, and while NB tumors formed, the model was crude as
MYCN expression was not robust, and strain background affected the level of
tumor development (Althoff et al. 2015). The transgenic mouse line LSL-MYCN;
Dbh-iCre (Cre-conditional induction of MYCN in dopamine- β- hydroxylaseexpressing cells) was created to overcome the lack of robust expression in all
mice strain (Althoff et al. 2015). The transgenic mice developed tumors with an
incidence of >75% regardless of the original strain. Specific expression of MYCN
in the neural crest produced abdominal tumors, which had a histology and
expression markers typical of human NB (Rickman et al. 2018). Genomic
analysis of the tumors revealed chromosomal aberrations syntenic to human NB,
specifically the murine partial gain of 11q, which is homologous to human
chromosome 17q – A frequent segmental chromosomal gain in human NB
(Vandesompele et al. 2005). The LSL-MYCN; Dbh-iCre mouse established a
model of advancing neuroblastoma from MYCN overexpression. This experiment
makes it plausible that similar results may be repeated in human NCC with
MYCN overexpression.
GWAS of HRNB tumors observed an association with LMO1
concentration and the development of aggressive cancers in human patients
(Wang K, Diskin SJ, Zhang H, et al. 2011). Researchers interested in the
influence of the oncogenes LMO1 and MYCN on NB created transgenic
zebrafish lines expressing human LMO1 (dβh LMO1,) MYCN(dβh MYCN), and
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LMO1 with MYCN (dβh MYCN; LMO1) under a dopamine-β-hydroxylase(dβh)
gene promoter (Zhu et al., 2017). The authors did not observe tumor formations
in the cell line dβh LMO1 when LMO1 expression was high in the absence of
high MCYN expression. The transgenic zebrafish that overexpressed MYCN only
accrued 20-30% tumor formation within its population, while the double mutant
dβh MYCN; LMO1 contained 80% tumor formation in its population of zebrafish.
The experiment showed that high expression of LMO1 when in collaboration with
high levels of MYCN expression leads to the accelerated onset of NB in vivo
(Zhu et al., 2017). The finding in the zebrafish model demonstrates that LMO1
interacts synergistically with MYCN to drive HRNB (Wang et al., 2011). This
model begs the question if LMO1 and MYCN interact similarly in human NB
development.
Animals models have proved a useful tool in studying many diseases,
though there are generally expensive, time-consuming, and lack scalability.
Researchers utilize primary cell models to address some of the animal model
limitations and gain the ability to observe the cellular properties of tissues in vitro.
In the case of NB, animal models have shown tumor formation in the
overexpression of MYCN and LMO1 in NCC. The primary NCC model was
developed to study the early stages of NB oncogenesis, assess the oncogenic
drivers, and characterized NB metastasis. The primary NCC were isolated from
the trunk neural tube of heterozygous p53+/- mice (embryonic day 9.5), and the
signal markers Sox10 and p75 verified the cells were uncommitted NCC (Olsen
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et al. 2019; Kim, J. et al. 2003). The extracted cells were transduced with N-MycIRES-GFP retrovirus and reintroduced into nude and C57BI/6 mice (Kawauchi et
al., 2012). There was 100% tumor penetrance in the eight nude mice and six
C57BI/6. NCC tumors were analyzed for chromosomal aberrations, which
revealed chromosomal gains and losses analogous to human MYCN amplified
NB (Olsen et al. 2019). The modification of murine neural crest cells to form
neuroblastoma by the overexpression of MYCN provided the evidence we could
translate this research into human neural crest cells.
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CHAPTER THREE
THE CREATION OF THE CELL LINE

A Human Neuroblastoma Model
The overexpression of LMO1 and MYCN in clinically observed human
tumors and their direct involvement in driving NB in animal and cell models
makes these two genes rather appropriate to study in a human system. A
popular human model for studying human diseases is the use of human stem
cells, either induced pluripotent stem (IPSC) or embryonic stem cells (ESCs).
IPSCs are reprogramed from adult cells to become pluripotent. The adult cell is
obtained from an individual that has a disease and is studied to develop a
patient-specific treatment. In the case of NB, there are examples of IPSC lines,
but these cell lines carry the genetic mutations of the patient, which is
advantageous in therapy design, but not for developmental research (Marin et al.
2019). The advantage of ESCs is that they permit researchers to modify the
human genome with the genes they wish to study and differentiate them into the
cells or tissue of their research model. Our laboratory is primarily concerned with
the development of neuroblastoma from neural crest cells, so ESC is the model
that permits us to examine the role of LMO1 and MYCN in the human
development of NCC.
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H1 Cell Line Design
The construction of the cell line required the development of plasmid
constructs that integrated LMO1 and MYCN into the H1 ESC genome and
permitted controlled expression. The TET-3G plasmid (AAVS1 Puro Tet3G
3xFLAG Twin Strep. Addgene catalog # 92099) was selected because of the
homologous arms in the plasmid specific to the AAVS1 locus and the TET-ON
inducible system. The homologous arm right is 837 bases and the homologous
arm left is 804 bases these sequences are specific to the AAVS1 locus at human
chromosome 19. The AAVS1 locus is popularly labeled the “safe harbor” as it
allows reliable integration of genes by homology driven repair under CRISPR
Cas9 modification (Sadelain, M., Papapetrou, E. P., & Bushman, F. D., 2011).
This technique in the past been shown to be highly efficient in modifying hESC
genomes, and experiments report low off-target alteration (Castaño et al., 2017).
TET-ON is a gene regulatory system that allows for the reliable and tight
expression of a gene in the presence of the molecule doxycycline – a small
molecule demonstrated not to produce cytotoxic effects or unwanted
differentiation of cells in gene therapy application (Das, A. T., Tenenbaum, L., &
Berkhout, B. 2016)
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Isolation of Human LMO1 and MYCN Genes
The LMO1 protein-encoding gene was isolated from 3-day old neural crest cells
cDNA to design the TET-3G LMO1 construct for integration into the AAVS1
locus.

Figure 2. Agarose Gel of the LMO1 Gene.
Isolated from Day 3 neural crest cell cDNA library maintained by the GarciaCastro laboratory. The products are 463 base pairs in length and are in lanes 2,
4, and 6.
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The MYCN cDNA was isolated from the pCDNA3-HA-human W- MYCN
(MYCN donor) plasmid to construct the TET-3G MYCN plasmid for integration to
the AAVS1 locus.

Figure 3. MYCN Donor Plasmid.
The pCDNA3-HA human plasmid contained MYCN protein-coding sequence
which was purchased from addgene to isolate the MYCN DNA sequence.
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Figure 4. Agarose Gel of the MYCN Gene.
Isolated from the MYCN donor plasmid. The products are 1392 bases and visible
in lanes 2, 4, and 6.

Creation of the TET-3G LMO1 and TET-3G MYCN Plasmids
The intention for the modification of the AAVS1 locus was to have a
heterogeneous integration of LMO1 and MYCN to chromosome 19. To
accomplish this task, we created the LMO1 construct controlled by the TET-ON
system and the MYCN construct controlled by the TET-ON system.
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Figure 5. TET-3G LMO1 Plasmid.
The LMO1 gene is regulated by the Tetracycline inducible system and flanked by
the HA-L and HA-R homologous arms specific to the AAVS1 locus on
chromosome 19.
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Figure 6. TET-3G MYCN Plasmid.
The MYCN gene is regulated by the Tetracycline inducible system and flanked
by the HA-L and HA-R homologous arms specific to the AAVS1 locus on
chromosome 19.
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Figure 7. Agarose Gel of TET-3G LMO1 and TET-3G MYCN Constructs.
The TET-3G LMO1 is in lanes 1-4 the product for lanes 2-4 is approximately 7.1
kb. The TET-3G MYCN is in lanes5-8 and lanes 5 and 7 are approximately 8kb
which correspond with expected product sizes.
Integration of TET-3G LMO1 into H1 hESC
Once the constructs were formed and isolated from bacterial cultures, it
was critical to validate the MYCN and LMO1 sequences before H1 hESC
nucleofection. The MYCN construct revealed a 24 base pair deletion at the 494nucleotide position inside the MYCN coding region. The MYCN donor plasmid
was sequenced, which reveal the same 24 base pair deletion. The LMO1
construct contained a single nucleotide polymorphism that resulted in a silent
mutation that did not alter the LMO1 protein. Based on the sequence analysis,
only the TET-3G LMO1 was nucleofected into the H1 hESC.
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Figure 8. TET-3G MYCN Sequence Alignment.
The TET-3G MYCN has a 24 base pair deletion in the gene which was
characterized from sequencing and Snap Gene alignment.

Figure 9. TET-3G LMO1 Sequence Alignment.
The TET-3G LMO1 construct contains a single nucleotide polymorphism that
results in a silent mutation.
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Figure 10. TET-3G LMO1 H1 hESC Sequence Alignment.
The alignment displays a fragmented sequence of the LMO1 coding gene
suggesting a small subset of the construct was integrated into the H1 hESC.
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CHAPTER FOUR
DISCUSSION AND CONCLUSION

Obstacles and Limitations
The project, in principle, is straightforward, but the development of the cell
line required multiple design modifications within a narrow time constraint. The
development of the LMO1 and MYCN constructs occurred quickly in the project
timeline, but of course, the MYCN mutation was identified once the construct was
isolated from bacterial cultures and sequenced. The MYCN repair was
complicated as the gene is 66% GC rich, and the region of the 24-base pair
deletion contains 92% GC content. These GC dense areas inhibited our ability to
modify the region with PCR as temperatures required for annealing were equal to
or higher than the polymerase activation temperature. Several piece-wise PCR
strategies were undertaken, but repair of the MYCN remained unsuccessful. An
alternative strategy considered was using a vector building company to synthesis
the MYCN gene; however, due to the GC content and size of our gene,
companies were unable to synthesize the gene. To address the GC content and
build a synthetic gene, I went through the MYCN gene and created synthetic
sequences that replaced cystines and guanines with thymine and adenine but did
not alter the protein sequence. This strategy proved to be expensive and outside
of the budgetary considerations of the project.
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There was a necessity for the constructs have a fluorescent tag to permit
screening and selection in the H1 hESC. The MYCN construct never proceeded
to the fluorescent modification stage, but the LMO1 construct was created quickly
and without issue. There were two fluorescent models for LMO1, the first utilizing
an EGFP gene flanked by two loci of X-over P1 (loxP) sites. This model intended
to identify the H1 hESC that contained LMO1 and depending on future
experimental parameters; the EGFP could be removed. This construct was never
synthesized in several Infusion strategies. The second model strategy integrates
the EGFP gene into the Tet-3G LMO1 construct, which would permanently
express EGFP in the H1 hESC. The EGFP expression was desirable for both
selection as well as future tracing in developmental experiments if the cells were
implanted into one of the Garcia-Castro animal models. The integration of the
EGFP gene did appear successful in the sequence analysis of the gene.
However, the transfection of the TET-3G LMO1 EGFP into HEK-293 cells did not
produce a fluorescent signal. This test of the EGFP was conducted with the
donor EGFP plasmid the gene was isolated from along with a commercial
plasmid, both controls produced clear fluorescent signals. The attempts to
develop a TET-3G LMO1 construct with a fluorescent marker were timeconsuming and unsuccessful, so I decided to continue the project with just the
TET-3G LMO1 construct and screen the LMO1 sequence in less efficient manner
relying on statistical probability for integration compared to single-cell isolation.
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MYCN Development
The MYCN gene on the TET-3G MYCN construct contained a 24nucleotide deletion at the 494-528 base pair region. To identify if the mutation
was a result of the construct engineering, I sequenced the MYCN donor plasmid.
The mutation was contained in the donor and was the source of the mutation.
The next question that emerged from the sequence analysis was, did the 24base pair deletion corresponds to an isoform that has been characterized in
cancer formation, particularly neuroblastoma. The mutated sequence was
uploaded to the NCBI Basic Local Alignment Search Tool (BLAST) to examine
the protein characteristics. The MYCN gene contained in the MYCN donor
plasmid mapped onto the human MYCN gene but with a 96.99% identity match
signifying this mutation has not been characterized previously and could not be
integrated into our H1 hESC model in this form. The MYCN construct underwent
many attempts to repair the gene using several subcloning strategies. Despite
my best efforts, the MYCN gene contains the 24-base pair deletion in both the
donor and the TET-3G MYCN plasmids.

LMO1 Development
The isolation of the LMO1 gene was straightforward as I was able
to extract it from the neural crest cell cDNA library maintained in the GarciaCastro lab. Sequencing of the LMO1 gene and analysis with NCBI BLASTX
revealed that the protein was an identical match to the human gene. Once the
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TET-3G LMO1 plasmid was a development, I repeated the same analysis, and
the results were the same, so we set aside a sample of the bacterial stock for
long-term storage and proceeded with the H1 hESC nucleofection with the TET3G LMO1 construct. I maintained the H1 hESC for about a week to permit the
nonintegrated plasmid to deteriorate so that analysis would only show sequence
analysis from integrated LMO1. The sequence analysis revealed a fragmented
sequence of the LMO1 gene along with the flanking sequence of the homologous
arms of the TET-3G LMO1 plasmid. However, given that the sequence of the
LMO1 gene was fragmented and weaker than the signal obtained from the
homologous arms sequence suggest the integration occurred in a small subset of
the ESCs, and therefore the cell population is a mixed colony. The establishment
of the H1 hESC with the LMO1 cell line is essential for the development of our
human NB model as LMO1 has been characterized as a significant oncogene in
zebrafish and several GWAS in the United States, Europe, and China.

Conclusion
The development of the TET-3G LMO1 H1 hESC is one component
of the human model to understand the role of LMO1 and MYCN in
neuroblastoma formation. Like with all scientific research, projects are never truly
finished, and there are some immediate experiments I would continue if time
permitted. The TET-3G LMO1 H1 ESC must undergo further colony screening to
obtain a pure population of stem cells that can be expanded and used in the
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development of the LMO1 plus MYCN inducible cell line. Once the LMO1 line is
stable, the next step will be to integrate the MYCN gene. Recently, there have
been several plasmids containing human MYCN cDNA that has been donated to
the company addgene. It would prove beneficial to locate the researchers that
developed these plasmids and inquire about their function and gene composition;
one of these plasmids may serve as the MYCN gene donor for our experiment.
Once the cell line is established, the next component will be to express the LMO1
and MYCN proteins with doxycycline treatments. It is important to mention that
before purchasing the TET-3G plasmid, I conducted toxicity tests on H1 hESC
with the doxycycline concentrations ranging from 0.25- 2 mg/ml over five days
and observed no changes in morphology or impediment to survival. Following the
doxycycline treatment to the LMO1 plus MYCN cell line and understanding the
parameters needed to maintain H1 hESC morphology, the cells can undergo
neural crest cell induction, in which the Garcia-Castro laboratory has an efficient
and proven protocol. My role in the project was the development of the H1 ESC
cell line, and given the parameters and obstacles we encountered, the members
of the Garcia-Castro lab and I believe the development of the H1 hESC LMO1
line is a solid starting point for the continuation of the human neuroblastoma
model.
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CHAPTER FIVE
METHODS AND MATERIALS

Plasmid Linearization and DNA Purification
PCR linearized the AAVS1 Puro Tet3G 3xFLAG Twin Strep (TET-3G) plasmid
with primers AAVS1 TET ON VEC forward and AAVS1 TET ON VEC reverse
(Table 1).
1. The PCR was conducted in a SimpliAmp™ Thermal Cycler, using
Phusion™ High-Fidelity polymerase under reaction specific cycle
conditions (see Table 1).

2. The PCR product ran on a 1% agarose gel mixed with GelRed® Nucleic
Acid Gel Stain and visualized in a Bio-Rad Gel DocTM XR+ Gel
Documentation System.
3. The PCR fragment was purified from the gel using the Zymoclean Gel
DNA Recovery Kit.
The PCR equipment and DNA purification process for LMO1, MYCN, and
EGFP are identical to methods used in TET-3G purification. The only
variations are the templates and specific PCR conditions are in Table 1.
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Cycling Conditions
One-time Initial denaturation: 95O C for 1 minute
35 cycles: Denature 95O C for 20 seconds
Annealing varied temperature for 10 seconds
Extension 72OC for varied times

Plasmid/
template

Forward
Primer

Reverse Primer

Purpose

AAVS1 TET ON

Annealing
Temp &
Extension
Time
64O C:10 sec

TET-3G

VEC TET ON

LMO1 cDNA

hLMO1 TET

hLMO1 TET

66O C:10 sec

Infusion

pCDNA3-HAhMYCN TET
human WMYCN
AAVS1 EGFP CMV EGFP
donor
Table 1. PCR Reactions.

hMYCN TET

58O C: 15 sec

Infusion

CMV EGFP

69O C: 25 sec

Infusion

Infusion

Cloning of LMO1 and MYCN into the TET-3G Plasmid
1. The Vector and inserts were ligated using the Takara In-Fusion® cloning
kit. The reaction formulations were performed with the Takara In-Fusion®
Molar Ratio Calculator tool.
2. The 10 ul cloning mixture was incubated for 15 minutes at 50 O C.
3. Following the ligation reaction, 2.5 ul of the TET-3G LMO1 and TET-3G
MYCN were added to separate 50 ul of Stellar Super Competent cells,
placed on ice for 30 minutes, and proceeded by 45 seconds of heat shock
at 42O C.
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4. 500ul of 37O C SOC media was added to the transformation reaction and
incubated at 37O C for 1 hour on the shaker.
5. The cells were plated on LB ampicillin agar plates and grown for 14 hours
at 37O C. Several bacterial colonies from both plasmids were picked and
expanded in 2 ml of LB media containing ampicillin for 12-16 hours.
6. A 600 ul sample taken from each 2 ml culture, and the DNA was extracted
using a ZymoPURE™ Plasmid Miniprep Kit.
7. Retrogen Inc sequenced the TET-3G LMO1 and TET-3G MYCN plasmids.
8. Based on sequence analysis, 10ul of the TET-3G LMO1 culture was
added to 90 ml of LB liquid media containing 90 ul of ampicillin and was
grown for 12 hours at 37O C on a shaker.
9. The TET-3G LMO1 DNA was collected with the ZymoPURE™ Plasmid
Midiprep Kit.

Creating the TET-3G LMO1 EGFP Plasmid
The TET-3G LMO1 plasmid was linearized by restriction digestion using the
enzymes HPA1 and NSI1, incubated at 37O C for 12 hours. The TET-3G LMO1
linear plasmid and EGFP fragment were ligated, verified, and expanded following
the methods used in the TET 3G LMO1 plasmid development (shown above).
H1 hESC Nucleofection and Colony Selection
1. Human ESCs were cultured in mTSeR medium with Rho Kinase (ROCK)inhibitor (10uM, Tocris) for 24 hours before electroporation.
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2. Cells were washed three times by Ca/Mg-Free PBS, digested by Accutase
(Stem Cell Tech) for 5 minutes, and harvested in mTSeR medium with
10uM ROCK-inhibitor.
3. Cells were dispersed into single cells and counted. Cells at 1.4-1.6x106
density are aliquoted into a 15ml conical tube for each nucleofection.
4. Cells were spun down at 90 x g for 3min at RT.
5. Cells were gently resuspended in 100ul of P3 Nucleofection Buffer
(Lonza) containing a combination of plasmids up to 10% of the total
volume (10ul max.). 15μg Cas9 plasmid, 15μg each sgRNA plasmid for
wild-type Cas9, and 30μg TET-3G LMO1 were used for nucleofection—
the ratio of 1:1:2 (cas9: sgRNA: donor plasmid should always be
maintained).
6. The cells in P3 buffer +TET-3G LMO1 plasmids were nucleofected using
the 4D-Nucleofector System (Lonza) using the CN-137 setting in single
100ul-cuvettes (Lonza).
7. Removed the cuvette and let the cells stand in the cuvette for 2-3mins in
the hood after 2-3mins added 500ul of warm mTSeR (with Ri).
8. Plate the cell in the Matrigel wells of a 6-well plate.
9. After 3-4 days, colonies were picked from single cells to screen for clones.
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APPENDIX A
AAVS1 INTERGRATION SITE
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The creation of the TET-3G LMO1 H1 hESC line was established with the
integration of the TET-ON and LMO1 DNA with the CRISPR Cas 9 gene-editing system.
The homologs arm on the TET-3G LMO1 have sequence specificity to the AAVS1
integration site on chromosome 19.

AAVS1 Locus.
Modified by CRISPR Cas 9 homologous directed repair with the AAVS1 arms of the
plasmid. The model represents a stand-in position for either the LMO1 or MYCN gene.
However, the actual construct would contain only one of the genes, and heterozygous
integration is the correct alteration of the H1 ESC genome.
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AAVS1 (adeno-associated virus integration site)

GAATTCCTAACTGCCCCGGGGCAGTCTGCTATTCATCCCCTTTACGCGGTG
CTACACACACTTGCTAGTATGCCGTGGGGACCCCTCCGGCCTGTAGACTCC
ATTTCCCAGCATTCCCCGGAGGAGGCCCTCATCTGGCGATTTCCACTGGGG
GCCTCGGAGCTGCGGACTTCCCAGTGTGCATCGGGGCACAGCGACTCCTG
GAAGTGGCCACTTCTGCTAATGGACTCCATTTCCCAGGCTCCCGCTACCTG
CCCAGCACACCCTGGGGCATCCGTGACGTCAGCAAGCCGGGCGGGGACC
GGAGATCCTTGGGGCGGTGGGGGGCCAGCGGCAGTTCCCAGGCGGCCCC
CGGGGCGGGCGGGCGGGCGGGTGGTGGCGGCGGTTGGGGCTCCGGGCG
CGTCGCTCGCTCGCTCGCTGGGCGGGCGGGCGGTGCGATGTCCGGAGAG
GATGGCCGGCGGCTGGCCCGGGGGCGGCGGCGCGGCTGCCCGGGAGCG
GCGACGGGAGCAGCTGCGGCAGTGGGGCGCGGGCGGGCGCCGAGCCTG
GCCCCGGAGAGCGCCGCGCCCGCACCGTCCGCTTCGAGCGCGCCGCCGA
GTTCCTGGCGGCCTGTGCGGGCGGCGACCTGGACGAGGCGCGTCTGATG
CTGCGCGCCGCCGACCCTGGCCCCGGCGCCGGAGCTCGACCCCGCCGGC
CGCCGCCCGCCCGCGCCGTGCTGGACTCCACCAACGCCGACGGTATCAGC
GCCCTGCACCAGGTCAGCGCCCCCCGCGGCGTCTCCCGGGGCCAGGTCC
ACCCTCTGCGCCACCTGGGGCATCCTCCTTCCCCGTTGCCAGTCTCGATCC
GCCCCGTCGTTACTGGCCCTGGGTTTNCACCCTATGCTGACACCCCGTTCC
AGTCCCCTTACCATTCCCTTCGACCACCCCACTTCCGAATTGGAGCGCTTCA
ACTGGCTGGGCTAGCACTCTGTGTGACACTCTGAAGCTCTACATTCCCTTC
GACCTACTCTCTTCGATTGGAGTCGCTTTAACTGGCCCTGGCTTTGGCAGC
CTGTGCTGACCCATCGAGTCCTCCTTACCATCCCTCCCTCGACTTCCCCTCT
TCCGATGTTGAGCCCCTCCAGCCGGTCCTGGACTTTGTCTCCTTCCCTGCC
CTGCCCTCTCCTGAACCTGAGCCAGCTCCCATAGCTCAGGTCTGGTCTATC
TGCCTGGCCCTGGCCATTGTCACTTTGCGCTGCCCTCCTCTCGCCCCCGAG
TGCCCTTGCTGTGCCGCCGGAACTCTGCCCTCTAACGCTGCCGTGCCGTCT
CTCTCCTGAGTCCGGACCACTTTGAGCTCTACTGGCTTCTGCGCGCCTCTG
GCCCACTGTTTCCCCTTCCCAGGCAGGTCCTGCTTTCTCTGACCAGCATTCT
CTCCCCTGGGCCTGTGCCGCTTTCTGTCTGCAGCTTGTGGCCTGGGTCACC
TCTACGGCTGGCCCAAGATCCTTCCCTGCCGCCTCCTTCAGGTTCCGTCTT
CCTCCACTCCCTCTTCCCCTTGCTCTCTGCTGTGTTGCTGCCCAAGGATGCT
CTTTCCGGAGCACTTCCTTCTCGGCGCTGCACCACGTGATGTCCTCTGAGC
GGATCCTCCCCGTGTCTGGGTCCTCTCCGGGCATCTCTCCTCCCTCACCCA
ACCCCATGCCGTGTTCACTCGCTGGGTTCCCTTTTCCTTCTCCTTCTGGGGC
CTGTGCCATCTCTCGTTTCTTAGGATGGCCTTCTCCGACGGATGTCTCCCTT
GCGTCCCGCCTCCCCTTCTTGTAGGCCTGCATCATCACCGTTTTTCTGGACA
ACCCCAAAGTACCCCGTCTCCCTGGCTTAGCACCTCTCCATCCTCTTGCTTT
CTTTGCCTGGACACCCCGTTCTCCTGTGGATTCGGGTCACCTCTCACTCCTT
TCATTTGGGCAGCTCCCCTACCCCCCTTACCTCTCTAGTCTGTGCTAGCTCT
TCCAGCCCCCTGTCATGGCATCTTCCAGGGGTCCGAGAGCTCAGCTAGTCT
TCTTCCTCCAACCCGGGCCCTATGTCCACTTCAGGACAGCATGTTTGCTGC
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CTCCAGGGATCCTGTGTCCCCGAGCTGGGACCACCTTATATTCCCAGGGCC
GGTTAATGTGGCTCTGGTTCTGGGTACTTTTATCTGTCCCCTCCACCCCACA
GTGGGGCCACTAGGGACAGGATTGGTGACAGAAAAGCCCCCATCCTTAGG
CCTCCTCCTTCCTAGTCTCCTGATATTCGTCTAACCCCCACCTCCTGTTAGG
CAGATTCCTTATCTGGTGACACACCCCCATTTCCTGGAGCCATCTCTCTCCT
TGCCAGAACCTCTAAGGTTTGCTTACGATGGAGCCAGAGAGGATCCTGGGA
GGGAGACTTGGCAGGGGGTGGGAGGGAAGGGGGGGATGCGTGACCTGCC
CGGTTCTCAGTGGCCACCCTGCGCTACCCTCTCCCAGAACCTGAGCTGCTC
TGACGCGGCTGTCTGGTGCGTTTCACTGATCCTGGTGCTGCAGCTTCCTTA
CACTTCCCAAGAGGAGAAGCAGTTTGGAAAAACAAAATCAGAATAAGTTGGT
CCTGAGTTCTAACTTTGGCTCTTCACCTTTCTAGNCCCCAATTTATATTGTTC
CTCCGTGCGTCAGTTTTACCTGTGAGATAAGGCCAGTAGCCACCCCCGTCC
TGGCAGGGCTGTGGTGAGGAGGGGGGTGTCCGTGTGGAAAACTCCCTTTG
TGAGAATGGTGCGTCCTAGGTGTTCACCAGGTCGTGGCCGCCTCTACTCCC
TTTCTCTTTCTCCATCCATCCTTCTTTCCTTAAAGAGCCCCCAGTGCTATCTG
GACATATTCCTCCGCCCAGAGCAGGGTCCGCTTCCCTAAGGCCCTGCTCTG
GGCTTCTGGGTTTGAGTCCTTGCAAGCCCAGGAGAGCGCTAGCTTCCCTGT
CCCCCTTCCTCGTCCACCATCTCATGCCCTGGCTCTCCTGCCCCTTCCTACA
GGGGTTCCTGGCTCTGCTCTTCAGACTGAGCCCCGTTCCCCTGCATCCCCG
TTCCCCTGCATCCCCCTTCCCCTGCATCCCCCAGAGCCCCAGGCCACCTAC
TTGGCCTGGAACCCCACGAGAGGCCACCCCAGCCCTGTCTACCAGGCTGA
CCTTTTGGGTGATTCTCCTCCAACTGTGGGGTGACTGCTTGGGCAAACTCA
CTCTTCGGGGTATCCCAGGAGGCCTGGAGCATTGGGGTGGGCTGGGGTTC
AGAGAGGAGGGATTCCCTCCAGGTTACGTGGCCAAGAAGCAGGGGAGCTG
GGTTTGGGTCAGGCTGGGTGTGGGGTGACCAGCTTATGCTGTTTGCCCAG
GACAGCCTAGTTTTAGCGCTGAAACCCTCAGTCCTAGGAAAACAGGGATGG
TTGGTCACTGTCTCTGGGTGACTCTTGATTCCCGGCCAGTTTCTCCACCTGG
GGCTGTGTTTCTCGTCCTGCATCCTTCTCCAGGCAGGTCCCCAAGCATCGC
CCCCCTGGCTGTTCCCAAGTTCTTAGGTACCCCACGTGGGTTTATGAACCA
CTTGGTGAGGCTGGTACCCTGCCCCCATTCCTGCACCCCAATTGCCTTAGT
GGCTAGGGGGTTGGGGGCTAGAGTAGGAGGGGCTGGAGCCAGGATTCTTA
GGGCTGAACAGAGCCGAGCTGGGGGCCTGGGCTCCTGGGTTTGAGAGAG
GAGGGGCTGGGGCCTGGACTCCTGGGTCCGAGGGAGGAGGGGCTGGGG
CCTGGACTCCTGGGTCTGAGGGTGGAGGGACTGGGGGCCTGGACTCCTGG
GTCCGAGGGAGGAGGGGCTGGGGCCTGGACTCGTGGGTCTGAGGGAGGA
GGGGTCGGGGGCCTGGACTTCTGGGTCTTAGGGAGGCGGGGCTGGGCCT
GGACCCCTGGGTCTGAATGGGGAGAGGCTGGGGGCCTGGACTCCTTCATC
TGAGGGCGGAAGGGCTGGGGCCTGGCCTCCTGGGTTGAATGGGGAGGGG
TTGGGCCTGGACTCTGGAGTCCCTGGTGCCCAGGCCTCAGGCATCTTTCAC
AGGGATGCCTGTAC
AAVS1 Homologous Arms Sequence.
The blue font corresponds to the homologous left arm of the TET-3G LMO1, and
the right font corresponds to the TET-3G LMO1 homologous right arm.
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TET-3G LMO1 Homologous Arms Alignment.
The alignment of the AAVS1 integration site with the TET-3G LMO1 plasmid
demonstrating the homology that permits integration into the H1 hESC.
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